MedTrace Logo

Fampridine Pregnancy Exposure Registry

NCT01532154 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-10-18

No results posted yet for this study

Summary

This is a global pregnancy registry to evaluate the outcomes of pregnancy in women with multiple sclerosis who have been exposed to prolonged-release fampridine since the first day of their last menstrual period prior to conception or at any time during pregnancy.

Conditions

Interventions

DRUG

Fampridine

As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532154 on ClinicalTrials.gov